e-therapeutics plc
ETXPF
$0.13
-$0.01-7.14%
OTC PK
| 01/31/2024 | 10/31/2023 | 07/31/2023 | 04/30/2023 | 01/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -32.52% | -15.39% | 9.50% | -7.06% | -11.38% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -32.52% | -15.39% | 9.50% | -7.06% | -11.38% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -32.52% | -15.39% | 9.50% | -7.06% | -11.38% |
| SG&A Expenses | 12.74% | -5.79% | -22.02% | -23.14% | -20.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.49% | 22.86% | 9.55% | 0.15% | -4.96% |
| Operating Income | -37.64% | -24.26% | -9.55% | -0.43% | 4.64% |
| Income Before Tax | -36.58% | -20.01% | -3.29% | 4.53% | 8.37% |
| Income Tax Expenses | -30.30% | -23.01% | -13.47% | -0.28% | 7.90% |
| Earnings from Continuing Operations | -37.72% | -19.50% | -1.63% | 5.35% | 8.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.72% | -19.50% | -1.63% | 5.35% | 8.46% |
| EBIT | -37.64% | -24.26% | -9.55% | -0.43% | 4.64% |
| EBITDA | -38.50% | -24.49% | -8.98% | 1.06% | 7.15% |
| EPS Basic | -26.06% | -4.15% | 14.40% | 18.52% | 18.61% |
| Normalized Basic EPS | -25.90% | -5.03% | 12.15% | 16.48% | 17.75% |
| EPS Diluted | -26.06% | -4.15% | 14.40% | 18.52% | 18.61% |
| Normalized Diluted EPS | -25.90% | -5.03% | 12.15% | 16.48% | 17.75% |
| Average Basic Shares Outstanding | 8.74% | 12.42% | 16.48% | 13.25% | 10.03% |
| Average Diluted Shares Outstanding | 8.74% | 12.42% | 16.48% | 13.25% | 10.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |